Literature DB >> 10090131

IGF-I levels rise and GH responses to GHRH decrease during long-term prednisone treatment in man.

M H Borges1, A C Pinto, F B DiNinno, C Camacho-Hübner, A Grossman, C E Kater, A M Lengyel.   

Abstract

Glucocorticoid excess is associated with a blunted GH response to GHRH. IGF-I levels in hypercortisolism are controversial and have been reported as low, normal or high. The aim of this study was to evaluate longitudinally time-dependent changes in the GH response to GHRH, IGF-I, IGFBP-3 and albumin values in patients during corticotherapy. Six patients received GHRH before and after one week and one month of prednisone administration (20-60 mg/d, orally). IGF-I, IGFBP-3 and albumin were determined in each test, at time 0. Ten normal controls were also evaluated in one occasion. There were no differences in basal GH values, GH response to GHRH, IGF-I and IGFBP-3 levels between controls and patients before starting corticotherapy. Albumin (g/l; mean+/-SE) values were lower in patients before treatment (31+/-4) than in controls (43+/-1). After one week of prednisone administration there was a significant decrease in peak GH (microg/l) levels (before: 18.8+/-7.4; 1 week: 5.0+/-1.3), which was maintained after one month (8.1+/-3.5). IGF-I (microg/l) levels increased significantly, from 145+/-23 to 205+/-52 after one week of therapy, reaching levels of 262+/-32 after one month. IGFBP-3 (mg/l) values did not increase significantly (before: 2.1+/-0.2; 1 week: 2.5+/-0.3; 1 month: 2.8+/-0.2). Albumin levels showed a significant rise both after one week (36+/-4) and one month (42+/-3) of corticotherapy. In summary, we observed a marked decrease in the GH response to GHRH after one week and one month of prednisone administration associated with an increase in circulating IGF-I and albumin values. The physiological implications of these findings are still uncertain. It is possible that glucocorticoids increase hepatic IGF-I and albumin synthesis, although other mechanisms may have a role.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10090131     DOI: 10.1007/BF03345472

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Monoclonal antibody-based immunoenzymometric assay for serum human growth hormone.

Authors:  J G Vieira; M T Lombardi; S K Nishida
Journal:  Braz J Med Biol Res       Date:  1990       Impact factor: 2.590

2.  Divergent effects of short term glucocorticoid excess on the gonadotropic and somatotropic axes in normal men.

Authors:  J D Veldhuis; G Lizarralde; A Iranmanesh
Journal:  J Clin Endocrinol Metab       Date:  1992-01       Impact factor: 5.958

Review 3.  Growth hormone axis in cushing's syndrome.

Authors:  B L Wajchenberg; B Liberman; D Giannella Neto; M Y Morozimato; M Semer; L O Bracco; L R Salgado; M Knoepfelmacher; M H Borges; A C Pinto; C E Kater; A M Lengyel
Journal:  Horm Res       Date:  1996

Review 4.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

5.  Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone.

Authors:  E Mazza; E Ghigo; S Goffi; M Procopio; E Imperiale; E Arvat; J Bellone; M F Boghen; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

6.  Insulin-like growth factor (IGF) I and II and IGF binding protein (IGFBP) 1, 2 and 3 in serum from patients with Cushing's syndrome.

Authors:  P Bang; M Degerblad; M Thorén; J Schwander; W Blum; K Hall
Journal:  Acta Endocrinol (Copenh)       Date:  1993-05

7.  Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure.

Authors:  M A Magiakou; G Mastorakos; M T Gomez; S R Rose; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

8.  Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I.

Authors:  R Ross; J Miell; E Freeman; J Jones; D Matthews; M Preece; C Buchanan
Journal:  Clin Endocrinol (Oxf)       Date:  1991-07       Impact factor: 3.478

9.  Somatomedin A levels in patients with Cushing's disease.

Authors:  M Thorén; K Hall; T Rähn
Journal:  Acta Endocrinol (Copenh)       Date:  1981-05

10.  Effect of human growth hormone-releasing hormone on GH secretion in Cushing's syndrome and non-endocrine disease patients treated with glucocorticoids.

Authors:  M Hotta; T Shibasaki; A Masuda; T Imaki; N Sugino; H Demura; N Ling; K Shizume
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

View more
  4 in total

1.  Use of desmopressin as an alternative to corticotropin-releasing hormone during inferior petrosal sinus sampling in a child with Cushing's disease.

Authors:  M H Gannagé-Yared; S Slaba; T Rizk; R-M Chidiac Wehbe
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

2.  Cognitive response to estradiol in postmenopausal women is modified by high cortisol.

Authors:  Laura D Baker; Sanjay Asthana; Brenna A Cholerton; Charles W Wilkinson; Stephen R Plymate; Pattie S Green; George R Merriam; Mark A Fishel; G Stennis Watson; Monique M Cherrier; Monica L Kletke; Pankaj D Mehta; Suzanne Craft
Journal:  Neurobiol Aging       Date:  2011-08-19       Impact factor: 4.673

3.  Growth and reproductive outcomes in congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-01

4.  Pituitary adenomas evade apoptosis via noxa deregulation in Cushing's disease.

Authors:  David T Asuzu; Reinier Alvarez; Patrick A Fletcher; Debjani Mandal; Kory Johnson; Weiwei Wu; Abdel Elkahloun; Paul Clavijo; Clint Allen; Dragan Maric; Abhik Ray-Chaudhury; Sharika Rajan; Zied Abdullaev; Diana Nwokoye; Kenneth Aldape; Lynnette K Nieman; Constantine Stratakis; Stanko S Stojilkovic; Prashant Chittiboina
Journal:  Cell Rep       Date:  2022-08-23       Impact factor: 9.995

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.